Eosinophilic Esophagitis Clinical Trial Pipeline Analysis of 15+ Companies by DelveInsight

News provided by

Jul 25, 2022, 11:30 ET

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. Key players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, AstraZeneca, Allakos, and others

LAS VEGAS, July 25, 2022 /PRNewswire/ -- DelveInsight's 'Eosinophilic Esophagitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline eosinophilic esophagitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the eosinophilic esophagitis pipeline domain.

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

DelveInsight's eosinophilic esophagitis pipeline report depicts a robust space with 15+ active players working to develop 15 + pipeline therapies for eosinophilic esophagitis treatment.
Leading eosinophilic esophagitis companies such as Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion, Quorum Innovations, Serpin Pharma, RAPT Therapeutics and others are evaluating novel eosinophilic esophagitis treatment drugs candidate to improve the treatment landscape.
Key eosinophilic esophagitis pipeline therapies in various stages of development includes Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab, NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.
In March 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn's Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn's Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In June 2021, the US FDA granted Orphan Drug designation to etrasimod for treating eosinophilic esophagitis. Currently, it is being investigated in the Phase II stage of development.
Lirentelimab (AK002), being developed by Allakos, targets Siglec-8, an inhibitory receptor found on the surface of mast cells and eosinophils. In the completed Phase II ENIGMA study, patients who had concomitant EoE showed esophageal eosinophil reduction and had less difficulty swallowing when treated with lirentelimab. Allakos has initiated a Phase III randomized, double-blind, placebo-controlled study of lirentelimab in patients with EoE.
The US FDA has cleared Landos Pharma's Investigational New Drug (IND) application for omilancor (BT-11), a novel, orally administered, gut-restricted LANCL2 agonist in development for the treatment of Eosinophilic Esophagitis (EoE). The company expects to initiate a randomized, double-blind, placebo-controlled Phase Ib study designed to evaluate the safety and pharmacokinetics of omilancor in patients with active Eosinophilic Esophagitis

Request a sample and discover the recent advances in eosinophilic esophagitis treatment @ Eosinophilic Esophagitis Pipeline Outlook

The eosinophilic esophagitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage eosinophilic esophagitis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the eosinophilic esophagitis pipeline landscape.

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated/allergen-mediated clinicopathological disease. Clinically, it is distinguished by signs of esophageal dysfunction. EoE's chronic inflammation causes eosinophilic esophagitis symptoms. However, the exact eosinophilic esophagitis causes are not known.

Early detection and eosinophilic esophagitis treatment are critical to preventing the progression of fibrotic abnormalities in the esophagus, which may be only partially reversible. For eosinophilic esophagitis diagnosis, an upper endoscopy including biopsies of the esophagus is required. Currently, eosinophilic esophagitis treatment includes dietary elimination diets, off-label usage of proton pump inhibitors, and glucocorticoid steroid formulations.

Find out more about eosinophilic esophagitis treatment @ Eosinophilic Esophagitis Treatment Guidelines

A snapshot of the Eosinophilic Esophagitis Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
APT-1011	Ellodi Pharma	Phase III	Glucocorticoid receptor agonists	Oral
CC-93538	Celgene Corporation	Phase III	Interleukin 13 inhibitors	Subcutaneous
AK002	Allakos	Phase III	Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors	Subcutaneous
Benralizumab	AstraZeneca	Phase III	Antibody-dependent cell cytotoxicity; Apoptosis stimulants	Subcutaneous
IRL201104	Revolo Biotherapeutics	Phase II	Immunomodulators	Intravenous
ESO-101	EsoCap AG	Phase II	Glucocorticoid receptor agonists	Oral
CALY-002	Calypso Biotech	Phase I	Interleukin 15 inhibitors	Intravenous
Barzolvolimab	Celldex Therapeutics	Phase I	Proto oncogene protein c-kit inhibitors	Subcutaneous

Learn more about the novel and emerging eosinophilic esophagitis pipeline therapies @ Eosinophilic Esophagitis Clinical Trials

Eosinophilic Esophagitis Therapeutics Assessment

The eosinophilic esophagitis pipeline report proffers an integral view of the eosinophilic esophagitis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Eosinophilic Esophagitis Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment By Mechanism of Action: Glucocorticoid receptor agonists, Interleukin 13 inhibitors, Interleukin 15 inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, Immunomodulators, Mast cell inhibitors, Immunomodulators, Proto oncogene protein c-kit inhibitors
Key Eosinophilic Esophagitis Companies: Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion, Quorum Innovations, Serpin Pharma, RAPT Therapeutics, and others
Key Eosinophilic Esophagitis Pipeline Therapies: Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab, NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.

Dive deep into rich insights for drugs for eosinophilic esophagitis, visit @ New Drug for Eosinophilic Esophagitis Treatment

Table of Contents

1.	Eosinophilic Esophagitis Pipeline Report Introduction
2.	Eosinophilic Esophagitis Pipeline Report Executive Summary
3.	Eosinophilic Esophagitis Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Eosinophilic Esophagitis Pipeline Therapeutics
6.	Eosinophilic Esophagitis Pipeline: Late Stage Products (Pre-registration)
7.	Eosinophilic Esophagitis Pipeline: Late Stage Products (Phase III)
7.1	APT-1011: Ellodi Pharma
8.	Eosinophilic Esophagitis Pipeline: Mid Stage Products (Phase II)
8.1	IRL201104: Revolvo Biotherapeutics
9.	Eosinophilic Esophagitis Pipeline: Early Stage Products (Phase I)
9.1	CALY-002: Calypso Biotech
10.	Eosinophilic Esophagitis Pipeline Therapeutic Assessment
11.	Inactive Products in the Eosinophilic Esophagitis Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Eosinophilic Esophagitis Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the eosinophilic esophagitis pipeline therapeutics, reach out @ Drugs for Eosinophilic Esophagitis

Related Reports

Eosinophilic Esophagitis Market

Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic esophagitis companies including Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, among others.

Eosinophilic Esophagitis Epidemiology Forecast

Eosinophilic Esophagitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted eosinophilic esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Eosinophilic Gastroenteritis Market

Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic gastroenteritis companies including Allakos, AstraZeneca, among others.

Eosinophilic Gastroenteritis Epidemiology Forecast

Eosinophilic Gastroenteritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted eosinophilic gastroenteritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Eosinophilic Disorder Pipeline

Eosinophilic Disorder Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic disorder companies, including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others.

Eosinophilic Disorder Market

Eosinophilic Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic disorder companies including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others.

Other Trending Reports